Middle East & Africa Herpes Market, By Virus Type (Herpes Simplex and Herpes Zoster), Product (Acyclovir, Docosanol, Valacyclovir, Famciclovir and Others), Drug Type (Prescription Drug and Over-the-counter Drug), Age (Adult and Pediatrics), Route Of Administration (Topical, Oral, and Parenteral), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies, and Others), End Users (Hospitals, Speciality Clinics, and Others) Country (South Africa, Saudi Arabia, UAE, Egypt, Israel, and Rest of Middle East and Africa) Industry Trends and Forecast to 2028.
Market Analysis and Insights: Middle East and Africa Herpes Market
Middle East & Africa herpes market is expected to gain significant growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyzes that the Middle East & Africa herpes market is growing with a CAGR of 5.3% in the forecast period of 2021 to 2028 and is expected to reach USD 38.43 million by 2028 from USD 26.54 million in 2020. Rising prevalence of herpes infections and increasing geriatric population are major drivers, which are expected to drive the growth of the market in the forecast period.
A growing number of people are affected with by the herpes simplex virus, which demands highly effective and advanced anti-herpetic treatment to minimize the risk during the treatment. The healthcare systems need highly advanced drugs for numerous different types of herpes during the treatment of patients. Therefore, major market players are highly focusing on product launches and product approvals. Additionally, governments and regulatory bodies are supporting market players by virtue of product approvals.
Rising prevalence of herpes diseases and increase in health expenditure across regions have accelerated the need for anti-herpetic drugs in healthcare facilities, which is driving the growth of the Middle East & Africa herpes market. In addition, surging volume of geriatric people is further propelling the market growth. However, high cost of anti-herpetic medicines and product recalls are anticipated to hinder market growth in the projected period. On the other hand, strategic initiatives by market players and soaring number of anti-herpetic drugs manufacturers act as an opportunity for this market and is expected to impel the market growth. However, disruption in supply chain of herpes drugs and injections during covid-19 and lack of workforce in pharma industries are key challenges for this market.
The Middle East & Africa herpes market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.
The Middle East & Africa Herpes Market Scope and Market Size
The Middle East & Africa herpes market is segmented on the basis of virus type, product, drug type, age, route of administration, distribution channel, and end users. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of virus type, the Middle East & Africa herpes market is segmented into herpes simplex and herpes zoster. In 2021, herpes simplex segment is expected to dominate the market due to rising prevalence of herpes infections owing to lack of awareness in the region.
- On the basis of product, the Middle East & Africa herpes market is segmented into acyclovir, docosanol, valacyclovir, famciclovir, and others. In 2021, acyclovir segment is expected to dominate the market owing to growing healthcare awareness among people and rising prevalence of herpes simplex virus.
- On the basis of drug type, the Middle East & Africa herpes market is segmented into prescription drug and over-the-counter drug. In 2021, prescription drug segment is expected to dominate the market because it is effective against herpes infection.
- On the basis of age, the Middle East & Africa herpes market is segmented into adult and pediatrics. In 2021, adult segment is expected to dominate the market owing to availability of better treatment options and increasing life expectancy of people.
- On the basis of route of administration, the Middle East & Africa herpes market is segmented into topical, oral and parenteral. In 2021, topical segment is expected to dominate the market as it is a non-invasive method with greater patient compliance.
- On the basis of distribution channel, the Middle East & Africa herpes market is segmented into hospitals pharmacies, retail pharmacies, drug stores, online pharmacies, and others. In 2021, hospital pharmacies segment is expected to dominate the market owing to novel product launches by market players.
- On the basis of end users, the Middle East & Africa herpes market is segmented into hospital, speciality clinics, and others. In 2021, hospitals segment is expected to dominate the market due to surge in patient pool for herpes treatment in the region.
Middle East & Africa Herpes Market Country Level Analysis
The Middle East & Africa herpes market is analyzed and market size information is provided based on virus type, product, drug type, age, route of administration, distribution channel, and end users.
Countries covered in the Middle East & Africa herpes market report are South Africa, Saudi Arabia, UAE, Egypt, Israel, and Rest of Middle East and Africa. South Africa is expected to dominate the Middle East & Africa herpes market in the forecast period due to increasing prevalence of herpes in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East & Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Rising healthcare expenditure and high prevalence of herpes infections in the region are creating new opportunities for players in the middle east & africa herpes market
South Africa is leading the market in Middle East & Africa region and herpes simplex segment is dominating the country due to rising demand for anti- herpetic drugs.
Middle East & Africa herpes market also provides you with detailed market analysis for every country growth in particular industry with the Middle East & Africa herpes market sales, impact of advancement in the Middle East & Africa herpes market and changes in regulatory scenarios with their support for the Middle East & Africa herpes market. The data is available for historic period 2010 to 2018.
Competitive Landscape and Middle East & Africa herpes market Share Analysis
Middle East & Africa herpes market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, and technology lifeline curve. The above data points provided are only related to the companies’ focus related to Middle East & Africa herpes market.
Major players covered in the report are Abbott, Apotex, Inc., Avet Pharmaceuticals, Inc., Bausch Health Companies, Inc. Cipla, Inc., Dr. Reddy’s Laboratories Ltd., EPI Health, Fresenius Kabi AG, GlaxoSmithKline plc., Glenmark Pharmaceutical Inc., USA, Maruho Co.,Ltd., Mylan N.V., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Zydus Pharmaceuticals, Inc., RECORDATI S.p.A., Aurobindo Pharma, Amneal Pharmaceuticals LLC, Slavia Pharm S.R.L., and Blistex, Inc. among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many product launches and agreements are also initiated by the companies worldwide, which are further accelerating the growth of the Middle East & Africa herpes market.
For instance,
- In November 2019, In November, Mylan N.V. announced the combination of the company with Upjohn, a division of Pfizer, The new company formed would be named Viatris. The merger of both the company to develop a combined firm has expanded its product portfolio, leading to increased demand for its product in the market.
- In September 2018, Avet Pharmaceuticals Inc. announced immediate availability of Acyclovir 200 mg Capsules. This launch enhanced Avet’s broad portfolio of generic oral solid products. This new drug launched by the company increased its sales in the market, leading to increased revenue in the future.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA HERPES MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 VIRUS TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 SUMMARY WRITE UP (NORTH AMERICA)
4.1.1 OVERVIEW
4.2 SUMMARY WRITE UP (EUROPE)
4.2.1 OVERVIEW
4.3 SUMMARY WRITE UP (ASIA-PACIFIC)
4.3.1 OVERVIEW
4.4 SUMMARY WRITE UP (SOUTH AMERICA)
4.4.1 OVERVIEW
4.5 SUMMARY WRITE UP (MIDDLE EAST AND AFRICA)
4.5.1 OVERVIEW
5 MIDDLE EAST AND AFRICA HERPES MARKET: REGULATIONS
5.1 THE U.S. REGULATORY FRAMEWORK
5.2 CANADA REGULATORY FRAMEWORK
5.3 THE EUROPE REGULATORY FRAMEWORK
5.4 INDIA REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.2 INCREASING GERIATRIC POPULATION
6.2.1 INCREASE IN PREVALENCE OF HERPES INFECTIONS
6.2.2 INCREASE IN NUMBER OF PRODUCT APPROVALS AND LAUNCHES
6.2.3 RISING NUMBER OF IMMUNOCOMPROMISED PEOPLE
6.3 RESTRAINTS
6.3.1 HIGH COST OF ANTI-HERPETIC MEDICINES
6.3.2 PRODUCT RECALL
6.4 OPPORTUNITIES
6.4.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS
6.4.2 INCREASING HEALTHCARE EXPENDITURE
6.4.3 SOARING NUMBER OF ANTI-HERPETIC DRUGS MANUFACTURERS
6.4.4 RISE IN NUMBER OF CONTRACT MANUFACTURING ORGANIZATIONS (CMO) AND CONTRACT RESEARCH ORGANIZATIONS (CRO)
6.5 CHALLENGES
6.5.1 DISRUPTION IN THE SUPPLY CHAIN OF HERPES DRUGS AND INJECTIONS DURING COVID-19
6.5.2 LACK OF WORKFORCE IN PHARMA INDUSTRIES
7 IMPACT OF COVID-19 ON MIDDLE EAST AND AFRICA HERPES MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY CHAIN
7.4 STRATEGIC DECISION BY MANUFACTURERS
7.5 CONCLUSION
8 MIDDLE EAST AND AFRICA HERPES MARKET, BY VIRUS TYPE
8.1 OVERVIEW
8.2 HERPES SIMPLEX
8.2.1 TYPE I
8.2.2 TYPE II
8.3 HERPES ZOSTER
9 MIDDLE EAST AND AFRICA HERPES MARKET, BY PRODUCT TYPE
9.1 OVERVIEW
9.2 ACYCLOVIR
9.3 DOCOSANOL
9.4 VALACYCLOVIR
9.5 FAMCICLOVIR
9.6 OTHERS
10 MIDDLE EAST AND AFRICA HERPES MARKET, BY DRUG TYPE
10.1 OVERVIEW
10.2 PRESCRIPTION DRUG
10.3 OVER-THE COUNTER DRUG
11 MIDDLE EAST AND AFRICA HERPES MARKET, BY AGE
11.1 OVERVIEW
11.2 ADULT
11.3 PEDIATRICS
12 MIDDLE EAST AND AFRICA HERPES MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 TOPICAL
12.3 ORAL
12.4 PARENTERAL
13 MIDDLE EAST AND AFRICA HERPES MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 HOSPITALS PHARMACIES
13.3 RETAIL PHARMACIES
13.4 DRUG STORES
13.5 ONLINE PHARMACIES
13.6 OTHERS
14 MIDDLE EAST AND AFRICA HERPES MARKET, BY END USERS
14.1 OVERVIEW
14.2 HOSPITALS
14.3 SPECIALITY CLINICS
14.4 OTHERS
15 MIDDLE EAST AND AFRICA HERPES MARKET, BY REGION
15.1 MIDDLE EAST AND AFRICA
15.1.1 SOUTH AFRICA
15.1.2 SAUDI ARABIA
15.1.3 U.A.E.
15.1.4 EGYPT
15.1.5 ISRAEL
15.1.6 REST OF MIDDLE EAST AND AFRICA
16 MIDDLE EAST AND AFRICA HERPES MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 GLAXOSMITHKILNE PLC
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENT
18.2 VIATRIS INC.
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENT
18.3 FRESENIUS KABI AG
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENT
18.4 PFIZER INC.
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENT
18.5 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 COMPANY SHARE ANALYSIS
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENT
18.6 ABBOTT
18.6.1 COMPANY SNAPSHOT
18.6.2 REVENUE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENT
18.7 AMNEAL PHARMACEUTICALS LLC
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENTS
18.8 APOTEX INC.
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENT
18.9 AUROBINDO PHARMA USA (A SUBSIDIARY OF AUROBINDO PHARMA)
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENT
18.1 AVET PHARMACEUTICALS INC.
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENT
18.11 BAUSCH HEALTH COMPANIES INC.
18.11.1 COMPANY SNAPSHOT
18.11.2 REVENUE ANALYSIS
18.11.3 PRODUCT PORTFOLIO
18.11.4 RECENT DEVELOPMENT
18.12 BLISTEX, INC.
18.12.1 COMPANY SNAPSHOT
18.12.2 PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENT
18.13 CIPLA, INC.
18.13.1 COMPANY SNAPSHOT
18.13.2 REVENUE ANALYSIS
18.13.3 PRODUCT PORTFOLIO
18.13.4 RECENT DEVELOPMENTS
18.14 DR. REDDY’S LABORATORIES LTD.
18.14.1 COMPANY SNAPSHOT
18.14.2 REVENUE ANALYSIS
18.14.3 PRODUCT PORTFOLIO
18.14.4 RECENT DEVELOPMENT
18.15 EPIHEALTH
18.15.1 COMPANY SNAPSHOT
18.15.2 PRODUCT PORTFOLIO
18.15.3 RECENT DEVELOPMENT
18.16 GLENMARK PHARMACEUTICAL INC., USA (A SUBSIDIARY OF GLENMARK PHARMACEUTICALS LTD.)
18.16.1 COMPANY SNAPSHOT
18.16.2 REVENUE ANALYSIS
18.16.3 PRODUCT PORTFOLIO
18.16.4 RECENT DEVELOPMENT
18.17 MARUHO CO.,LTD.
18.17.1 COMPANY SNAPSHOT
18.17.2 PRODUCT PORTFOLIO
18.17.3 RECENT DEVELOPMENTS
18.18 RECORDATI S.P.A.
18.18.1 COMPANY SNAPSHOT
18.18.2 REVENUE ANALYSIS
18.18.3 PRODUCT PORTFOLIO
18.18.4 RECENT DEVELOPMENT
18.19 SLAVIA PHARM S.R.L.
18.19.1 COMPANY SNAPSHOT
18.19.2 PRODUCT PORTFOLIO
18.19.3 RECENT DEVELOPMENT
18.2 SUN PHARMACEUTICAL INDUSTRIES LTD
18.20.1 COMPANY SNAPSHOT
18.20.2 REVENUE ANALYSIS
18.20.3 PRODUCT PORTFOLIO
18.20.4 RECENT DEVELOPMENT
18.21 ZYDUS PHARMACEUTICALS, INC.
18.21.1 COMPANY SNAPSHOT
18.21.2 PRODUCT PORTFOLIO
18.21.3 RECENT DEVELOPMENT
19 QUESTIONNAIRE
20 RELATED REPORTS
List of Table
LIST OF TABLES
TABLE 1 THE EMA HAS SEVEN SCIENTIFIC COMMITTEES THAT CARRY OUT ITS SCIENTIFIC ASSESSMENTS:
TABLE 2 HEALTHCARE EXPENDITURE IN ASIA-PACIFIC
TABLE 3 MANUFACTURERS OF ANTI-HERPETIC DRUGS
TABLE 4 MIDDLE EAST AND AFRICA HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA HERPES SIMPLEX IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA HERPES SIMPLEX IN HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA HERPES ZOSTER IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA HERPES MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA ACYCLOVIR IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA DOCOSANOL IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA VALACYCLOVIR IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA FAMCICLOVIR IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA OTHERS IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA HERPES MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA PRESCRIPTION DRUG IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA OVER-THE COUNTER DRUG IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA HERPES MARKET, BY AGE, 2019-2028 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA ADULT IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA PEDIATRICS IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA HERPES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA TOPICAL IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA ORAL IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA PARENTERAL IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA HERPES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA HOSPITALS PHARMACIES IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA RETAIL PHARMACIES IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA DRUG STORES IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA ONLINE PHARMACIES IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA OTHERS IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA HERPES MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA HOSPITALS IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA SPECIALITY CLINICS IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA OTHERS IN HERPES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA HERPES MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA HERPES SIMPLEX IN HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA HERPES MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA HERPES MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA HERPES MARKET, BY AGE, 2019-2028 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA HERPES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA HERPES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA HERPES MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 43 SOUTH AFRICA HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 44 SOUTH AFRICA HERPES SIMPLEX IN HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 45 SOUTH AFRICA HERPES MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 46 SOUTH AFRICA HERPES MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 47 SOUTH AFRICA HERPES MARKET, BY AGE, 2019-2028 (USD MILLION)
TABLE 48 SOUTH AFRICA HERPES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 49 SOUTH AFRICA HERPES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 50 SOUTH AFRICA HERPES MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 51 SAUDI ARABIA HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 52 SAUDI ARABIA HERPES SIMPLEX IN HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 53 SAUDI ARABIA HERPES MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 54 SAUDI ARABIA HERPES MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 55 SAUDI ARABIA HERPES MARKET, BY AGE, 2019-2028 (USD MILLION)
TABLE 56 SAUDI ARABIA HERPES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 57 SAUDI ARABIA HERPES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 58 SAUDI ARABIA HERPES MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 59 U.A.E. HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 60 U.A.E. HERPES SIMPLEX IN HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 61 U.A.E. HERPES MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 62 U.A.E. HERPES MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 63 U.A.E. HERPES MARKET, BY AGE, 2019-2028 (USD MILLION)
TABLE 64 U.A.E. HERPES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 65 U.A.E. HERPES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 66 U.A.E. HERPES MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 67 EGYPT HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 68 EGYPT HERPES SIMPLEX IN HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 69 EGYPT HERPES MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 70 EGYPT HERPES MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 71 EGYPT HERPES MARKET, BY AGE, 2019-2028 (USD MILLION)
TABLE 72 EGYPT HERPES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 73 EGYPT HERPES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 74 EGYPT HERPES MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 75 ISRAEL HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 76 ISRAEL HERPES SIMPLEX IN HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
TABLE 77 ISRAEL HERPES MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 78 ISRAEL HERPES MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 79 ISRAEL HERPES MARKET, BY AGE, 2019-2028 (USD MILLION)
TABLE 80 ISRAEL HERPES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 81 ISRAEL HERPES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 82 ISRAEL HERPES MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 83 REST OF MIDDLE EAST AND AFRICA HERPES MARKET, BY VIRUS TYPE, 2019-2028 (USD MILLION)
List of Figure
LIST OF FIGURES
FIGURE 1 MIDDLE EAST AND AFRICA HERPES MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA HERPES MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA HERPES MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA HERPES MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA HERPES MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA HERPES MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA HERPES MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA HERPES MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 MIDDLE EAST AND AFRICA HERPES MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA HERPES MARKET: SEGMENTATION
FIGURE 11 INCREASE IN PREVALENCE OF HERPES INFECTIONS AND RISE IN HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA HERPES MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 HERPES SIMPLEX SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA HERPES MARKET IN 2021 & 2028
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA HERPES MARKET
FIGURE 14 NUMBER OF PERSON AGED 60 YEARS OR OVER BY REGIONS IN 2020 (IN MILLIONS)
FIGURE 15 MARKET GROWTH IN CLINICAL CRO (IN USD MILLIONS)
FIGURE 16 MIDDLE EAST AND AFRICA HERPES MARKET : BY VIRUS TYPE, 2020
FIGURE 17 MIDDLE EAST AND AFRICA HERPES MARKET : BY VIRUS TYPE, 2019-2028 (USD MILLION)
FIGURE 18 MIDDLE EAST AND AFRICA HERPES MARKET : BY VIRUS TYPE, CAGR (2021-2028)
FIGURE 19 MIDDLE EAST AND AFRICA HERPES MARKET : BY VIRUS TYPE, LIFELINE CURVE
FIGURE 20 MIDDLE EAST AND AFRICA HERPES MARKET : BY PRODUCT TYPE, 2020
FIGURE 21 MIDDLE EAST AND AFRICA HERPES MARKET : BY PRODUCT TYPE, 2019-2028 (USD MILLION)
FIGURE 22 MIDDLE EAST AND AFRICA HERPES MARKET : BY PRODUCT TYPE, CAGR (2021-2028)
FIGURE 23 MIDDLE EAST AND AFRICA HERPES MARKET : BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 24 MIDDLE EAST AND AFRICA HERPES MARKET : BY DRUG TYPE, 2020
FIGURE 25 MIDDLE EAST AND AFRICA HERPES MARKET : BY DRUG TYPE, 2019-2028 (USD MILLION)
FIGURE 26 MIDDLE EAST AND AFRICA HERPES MARKET : BY DRUG TYPE, CAGR (2021-2028)
FIGURE 27 MIDDLE EAST AND AFRICA HERPES MARKET : BY DRUG TYPE, LIFELINE CURVE
FIGURE 28 MIDDLE EAST AND AFRICA HERPES MARKET: BY AGE, 2020
FIGURE 29 MIDDLE EAST AND AFRICA HERPES MARKET: BY AGE, 2019-2028 (USD MILLION)
FIGURE 30 MIDDLE EAST AND AFRICA HERPES MARKET: BY AGE, CAGR (2021-2028)
FIGURE 31 MIDDLE EAST AND AFRICA HERPES MARKET: BY AGE, LIFELINE CURVE
FIGURE 32 MIDDLE EAST AND AFRICA HERPES MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 33 MIDDLE EAST AND AFRICA HERPES MARKET: BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
FIGURE 34 MIDDLE EAST AND AFRICA HERPES MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 35 MIDDLE EAST AND AFRICA HERPES MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 36 MIDDLE EAST AND AFRICA HERPES MARKET: DISTRIBUTION CHANNEL, 2020
FIGURE 37 MIDDLE EAST AND AFRICA HERPES MARKET: DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
FIGURE 38 MIDDLE EAST AND AFRICA HERPES MARKET: DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 39 MIDDLE EAST AND AFRICA HERPES MIDDLE EAST AND AFRICA MARKET: DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 40 MIDDLE EAST AND AFRICA HERPES MARKET: BY END USERS, 2020
FIGURE 41 MIDDLE EAST AND AFRICA HERPES MARKET: BYEND USERS, 2019-2028 (USD MILLION)
FIGURE 42 MIDDLE EAST AND AFRICA HERPES MARKET: BY END USERS, CAGR (2021-2028)
FIGURE 43 MIDDLE EAST AND AFRICA HERPES MARKET: BY END USERS, LIFELINE CURVE
FIGURE 44 MIDDLE EAST AND AFRICA HERPES MARKET: SNAPSHOT (2020)
FIGURE 45 MIDDLE EAST AND AFRICA HERPES MARKET: BY COUNTRY (2020)
FIGURE 46 MIDDLE EAST AND AFRICA HERPES MARKET: BY COUNTRY (2021 & 2028)
FIGURE 47 MIDDLE EAST AND AFRICA HERPES MARKET: BY COUNTRY (2020 & 2028)
FIGURE 48 MIDDLE EAST AND AFRICA HERPES MARKET: BY VIRUS TYPE (2021-2028)
FIGURE 49 MIDDLE EAST AND AFRICA HERPES MARKET: COMPANY SHARE 2020 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
